



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	09/997,131-Conf. #3384
				Filing Date	November 30, 2001
				First Named Inventor	Daniel R. Soppet
				Art Unit	1646
				Examiner Name	M. T. Brannock
Sheet	1	of	1	Attorney Docket Number	PZ037P1C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
M	AE	GREEN et al., "The CMRF-35 mAb recognizes a second leukocyte membrane molecule with a domain similar to the poly Ig receptor," <i>Int'l Immunol.</i> , 10(7):891-899 (1998).		
	AF	MALONEY et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients With Recurrent B-Cell Lymphoma," <i>Blood</i> , 84(8):2457-2466 (Oct. 15, 1994).		
	AG	SUI et al., "IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes," <i>Biochem. and Biophys. Res. Commun.</i> , 319:920-928 (2004).		
	AH	VAN DER LUBBE et al., "Treatment with a Chimeric CD4 Monoclonal Antibody is Associated with a Relative Loss of CD4 ⁺ /CD45RA ⁺ Cells in Patients with Rheumatoid Arthritis," <i>J. Autoimmun.</i> , 10:87-97 (1997).		
	AI	RILEY et al., "CD20: a gene in search of a function," <i>Semin. Oncol.</i> , 27(6 Suppl. 12):17-24 (Dec. 2000) (abstract only).		
	AJ	O'NEAL, CHERYL, "Rituximab," <i>Clin. J. Oncol. Nursing</i> , 5(2):75-76 (Mar.-Apr. 2001).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	6/26/05
-----------------------	--	--------------------	---------